The AAT Replacement Therapy market is a subset of the larger Respiratory Drugs market. It is focused on the treatment of Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder that can cause lung and liver damage. AAT Replacement Therapy is a form of enzyme replacement therapy, which involves the administration of a recombinant form of the AAT protein to replace the deficient protein in the body. This therapy is used to reduce the risk of lung and liver damage in patients with AATD. The AAT Replacement Therapy market is expected to experience steady growth in the coming years, driven by increasing awareness of AATD and the availability of new treatments. Additionally, the increasing prevalence of AATD is expected to drive the market growth. Some of the major companies in the AAT Replacement Therapy market include Grifols, CSL Behring, Shire, and Chiesi Farmaceutici. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
